The EPS projection of ImmunoGen, Inc. (NASDAQ:IMGN) for quarter ended 2016-09-30 is $-0.4. Last week, the projection for EPS was $-0.4 against target of $-0.4, a month earlier. While 2-months ago, this projection was $-0.4 versus forecast of $-0.4a quarter months earlier, posting a deviation of 0%.
ImmunoGen, Inc. (NASDAQ:IMGN) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 0.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 0, and 0, correspondingly.
The per-share earnings downgrade for ImmunoGen, Inc. (NASDAQ:IMGN) in the preceding 30 and 120 were 0 and 0. While in 60 and 90 days were 0, and 0, in that order.
ImmunoGen, Inc. (NASDAQ:IMGN) EPS target was $-0.4 for the quarter closed 3. It was based on 5 calls. As on 2016-04-29 the EPS was $-0.37. The change was $-0.07, posting a deviation of -23.33%. The price projections gave a standard deviation of 0.04.
Quarterly Sales Estimates
ImmunoGen, Inc. (NASDAQ:IMGN) sales prediction for the fiscal 2016 stands at $16.95 and the median estimate is at $16.95. Almost 2 analysts gave sales target.
Among this, the highest sales estimate is $17.8 while the lowest target is $16.1 showing standard deviation of 1.202%.
As many as 2 analysts have positive sales targets revision while 2 reduced sales estimates, posting a deviation of 0%.
Last month, 2 experts have positive sales number revision. Also, 2 research groups lowered the sales projections, posting a deviation of 0.533%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast, posting a deviation of -8.194%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...